Citations

Showing 10 of 108104 citations.

COVID-19 Outcomes in Patients Hospitalised with Acute Myocardial Infarction (AMI): A Protocol for Systematic Review and Meta-Analysis
Shaw, Peter , Senguttuvan, Nagendra Boopathy , Raymond, G, Sankar, Srivarshini, Mukherjee, Anirban Goutam , Kunale, Milind , Muthukaliannan, Gothandam Kodiveri , Baxi, Siddhartha , Mani, Ravishankar Ram, Rajagopal, Mogana, Samiappan, Suja , Krishnan, Sunil , Jayaraj, Rama , Ram, M. Ravishankar , Krishnan, Sunil , Ram, M Ravishankar , Shaw, Peter , Muthukaliannan, Gothandam Kodiveri , Jayaraj, Rama , Rajagopal, Mogana

Mayo Clinic

COVID | January 25, 2022 | Volume: 2 | Issue: 2 | Pages: 138-147

10.3390/covid2020010 Get It

Background: Patients with cardiovascular disease and risk factors for cardiovascular illness are more likely to acquire severe 2019 novel coronavirus (2019-nCoV) infection (COVID-19). COVID-19 infection is more common in patients with cardiovascular illness, and they are more likely to develop severe symptoms. Nevertheless, whether COVID-19 patients are more likely to develop cardiovascular disorders such as acute myocardial infarction (AMI) is still up for debate. Methods: We will follow the preferred reporting items for systematic review and meta-analysis (PRISMA) to report our final study, including a systematic search of the bibliographic database using the appropriate combination of search terms or keywords. The choice of search terms is discussed in more detail later in this paper. The obtained results will be screened, and the data extracted from the studies selected for systematic review will be based on the predefined inclusion and exclusion criteria. Using the obtained data, we will then perform the associated Meta-analysis to generate the forest plot (pooled estimated effect size Hazard Ratio (HR) and 95% Confidence Intervals (CI) values) using the random-effects model. Any publication bias will be assessed using the funnel plot symmetry, Orwin and Classic Fail-Safe N Test and Begg and Mazumdar Rank Correlation Test and Egger’s Test of the intercept. In cases where insufficient data occur, we will also perform a qualitative review. Discussion: This systematic review will explore COVID-19 clinical outcomes, especially survival in patients hospitalised with Acute Myocardial Infarction, by utilising a collection of previously published data on hospitalised COVID-19 patients and Myocardial Infarction. Highlighting these prognostic survival analyses of COVID-19 patients with AMI will have significant clinical implications by allowing for better overall treatment strategies and patient survival estimates by offering clinicians a method of quantitatively analysing the pattern of COVID-19 cardiac complications.
Validation of cardiogenic shock phenotypes in a mixed cardiac intensive care unit population
Jentzer, Jacob C. , Soussi, Sabri , Lawler, Patrick R. , Kennedy, Jason , Jentzer, Jacob C , Lawler, Patrick , Kashani, Kianoush

Mayo Clinic

Catheterization and Cardiovascular Interventions | January 25, 2022 | Volume: 99 | Issue: 4 | Pages: 1006-1014

10.1002/ccd.30103 | PMID 35077592 Get It

AbstractBackgroundProposed phenotypes have recently been identified in cardiogenic shock (CS) populations using unsupervised machine learning clustering methods. We sought to validate these phenotypes in a mixed cardiac intensive care unit (CICU) population of patients with CS.MethodsWe included Mayo Clinic CICU patients admitted from 2007 to 2018 with CS. Agnostic K means clustering was used to assign patients to three clusters based on admission values of estimated glomerular filtration rate, bicarbonate, alanine aminotransferase, lactate, platelets, and white blood cell count. In‐hospital mortality and 1‐year mortality were analyzed using logistic regression and Cox proportional‐hazards models, respectively.ResultsWe included 1498 CS patients with a mean age of 67.8 ± 13.9 years, and 37.1% were females. The acute coronary syndrome was present in 57.3%, and cardiac arrest was present in 34.0%. Patients were assigned to clusters as follows: Cluster 1 (noncongested), 603 (40.2%); Cluster 2 (cardiorenal), 452 (30.2%); and Cluster 3 (hemometabolic), 443 (29.6%). Clinical, laboratory, and echocardiographic characteristics differed across clusters, with the greatest illness severity in Cluster 3. Cluster assignment was associated with in‐hospital mortality across subgroups. In‐hospital mortality was higher in Cluster 3 (adjusted odds ratio [OR]: 2.6 vs. Cluster 1 and adjusted OR: 2.0 vs. Cluster 2, both p < 0.001). Adjusted 1‐year mortality was incrementally higher in Cluster 3 versus Cluster 2 versus Cluster 1 (all p < 0.01).ConclusionsWe observed similar phenotypes in CICU patients with CS as previously reported, identifying a gradient in both in‐hospital and 1‐year mortality by cluster. Identifying these clinical phenotypes can improve mortality risk stratification for CS patients beyond standard measures.
NBS1-CtIP–mediated DNA end resection suppresses cGAS binding to micronuclei
Abdisalaam, Salim , Mukherjee, Shibani, Sinha, Debapriya, Ortega, Janice , Li, Guo‐Min , Sadek, Hesham A. , Asaithamby, Aroumougame , Li, Guo-Min , Asaithamby, Aroumougame , Bhattacharya, Souparno , Kumari, Sharda , Krishnan, Sunil

Mayo Clinic

Nucleic Acids Research | January 25, 2022 | Volume: 50 | Issue: 5 | Pages: 2681-2699

10.1093/nar/gkac079 | PMID 35189637 Get It

Abstract Cyclic guanosine monophosphate–adenosine monophosphate synthase (cGAS) is activated in cells with defective DNA damage repair and signaling (DDR) factors, but a direct role for DDR factors in regulating cGAS activation in response to micronuclear DNA is still poorly understood. Here, we provide novel evidence that Nijmegen breakage syndrome 1 (NBS1) protein, a well-studied DNA double-strand break (DSB) sensor—in coordination with Ataxia Telangiectasia Mutated (ATM), a protein kinase, and Carboxy-terminal binding protein 1 interacting protein (CtIP), a DNA end resection factor—functions as an upstream regulator that prevents cGAS from binding micronuclear DNA. When NBS1 binds to micronuclear DNA via its fork-head–associated domain, it recruits CtIP and ATM via its N- and C-terminal domains, respectively. Subsequently, ATM stabilizes NBS1’s interaction with micronuclear DNA, and CtIP converts DSB ends into single-strand DNA ends; these two key events prevent cGAS from binding micronuclear DNA. Additionally, by using a cGAS tripartite system, we show that cells lacking NBS1 not only recruit cGAS to a major fraction of micronuclear DNA but also activate cGAS in response to these micronuclear DNA. Collectively, our results underscore how NBS1 and its binding partners prevent cGAS from binding micronuclear DNA, in addition to their classical functions in DDR signaling.
The Ever-Important Role of Ethics in Plastic Surgery Today
Teven, Chad M., Bluebond-Langner, Rachel, Rohrich, Rod J., Bluebond‐Langner, Rachel , Teven, Chad M., Rohrich, Rod J.

Mayo Clinic

Plastic & Reconstructive Surgery | January 25, 2022 | Volume: 149 | Issue: 2 | Pages: 520-522

10.1097/prs.0000000000008773 | PMID 35077433 Get It

Summary: As the field of plastic surgery continues to advance, so too do the number and complexity of ethical challenges faced by plastic surgeons. There is a paucity of literature, however, focusing on ethics in plastic surgery. Therefore, the authors offer a timely special topic series discussing ethical issues relevant to the field of plastic surgery. The goals of this series are four-fold: (1) to increase awareness of both frequently and less commonly encountered ethical issues in plastic surgery, (2) to foster discussion and debate of relevant and significant ethical issues, (3) to facilitate clinical ethics education and scholarship in plastic surgery, and (4) to apply an understanding and analysis of ethical issues in a way that optimizes clinical decision-making and delivery of patient care. In this introductory article, the authors discuss the current state of medical ethics scholarship in plastic surgery and introduce the first of several topics that will be detailed in the series. Ultimately, the hope is that increased awareness of the ethical challenges faced by surgeons and patients will improve the practice of plastic surgery.
The ‘Fault’ Lies in the Choroid: Peripapillary Intrachoroidal Cavitation Presenting with Progressive Vision Loss
Bhatti, M. Tariq , Chen, John J. , Mansukhani, Sasha A. , Dolan, Joseph, Olatunji, Sunday, Chen, John J , Mansukhani, Sasha A , Belamkar, Aditya V. , Dolan, Joseph, Olatunji, Sunday

Mayo Clinic

Neuro-Ophthalmology | January 25, 2022 | Volume: 46 | Issue: 4 | Pages: 254-257

10.1080/01658107.2021.2009521 | PMID 35859631 Get It

INTRIGUE: A phase III, randomized, open-label study to evaluate the efficacy and safety of ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib
Schöffski, Patrick , Razak, Albiruni Ryan Abdul, Attia, Steven , Cesne, Axel Le, Su, Ying , Meade, Julie Nicole, Wang, Tao , Sherman, Matthew L. , Ruiz‐Soto, Rodrigo , Heinrich, Michael C. , Jones, Robin L. , Gelderblom, Hans , George, Suzanne , Mehren, Margaret von , Zalcberg, John , Kang, Yoon‐Koo , Trent, Jonathan C. , Blay, Jean‐Yves , Bauer, Sebastian

Mayo Clinic

Journal of Clinical Oncology | January 25, 2022 | Volume: 40 | Issue: 36_suppl | Pages: 359881-359881

10.1200/jco.2022.40.36_suppl.359881 Get It

359881 Background: Sunitinib is approved for advanced gastrointestinal stromal tumor (GIST) after imatinib failure. Ripretinib, a broad-spectrum KIT and PDGFRA switch-control tyrosine kinase inhibitor (TKI), is indicated for the treatment of adult patients (pts) with GIST who received prior treatment with 3 or more TKIs, including imatinib. We compared the efficacy and safety of ripretinib vs sunitinib in pts with advanced GIST who progressed on or were intolerant to imatinib. Methods: This multicenter, global, randomized, open-label phase 3 study (NCT03673501) enrolled adult pts with GIST who progressed on or had intolerance to imatinib. Pts were randomized 1:1 to ripretinib 150 mg once daily (QD) or sunitinib 50 mg QD (4 wks on/2 wks off). Randomization was stratified by KIT mutational status and imatinib intolerance. The primary endpoint was progression-free survival (PFS) by independent radiologic review (IRR) using modified RECIST version 1.1. Key secondary endpoints were objective response rate (ORR) by IRR and overall survival (OS). Hierarchical testing was performed for primary and key secondary endpoints in a prespecified sequence; testing pts with a KIT exon 11 primary mutation (Ex11 intention-to-treat [ITT] population) preceded the all-patient (AP) ITT population. Data cutoff was 1 Sep 2021; final analyses of PFS and ORR and the first interim analysis of OS were conducted. Results: A total of 453 pts were randomized to ripretinib (n = 226; Ex11 ITT, n = 163) or sunitinib (n = 227; Ex11 ITT, n = 164). Median age was 60 yrs (range 18–88) and most pts were white (66.2%) males (62.0%). PFS was not statistically different between ripretinib and sunitinib in the Ex11 ITT (hazard ratio [HR] 0.88, 95% CI 0.66, 1.16; P = 0.36; median 8.3 vs 7.0 mos) or in the AP populations (HR 1.05, 95% CI 0.82, 1.33; P = 0.72; median 8.0 vs 8.3 mos). ORR was numerically higher for ripretinib vs sunitinib in the Ex11 ITT (23.9% vs 14.6%; difference 9.3%, 95% CI 0.7, 17.8; nominal P = 0.03) and AP ITT populations (21.7% vs 17.6%; difference 4.2%, 95% CI −3.2, 11.5; nominal P = 0.27). OS data was highly immature; median OS was not reached in either arm. Fewer pts in the ripretinib arm experienced Grade 3-4 (G3-4) treatment-emergent adverse events (TEAEs) vs sunitinib (41.3% vs 65.6%). Among G3-4 TEAEs with a difference ≥5% between arms, ripretinib had fewer events vs sunitinib (hypertension [8.5% vs 26.7%], palmar-plantar erythrodysesthesia [1.3% vs 10.0%], neutropenia [0% vs 6.3%], and neutrophil count decreased [0% vs 7.2%]). Conclusions: The PFS in both arms was longer than PFS achieved by sunitinib in its pivotal phase 3 trial. While the PFS for ripretinib did not meet the primary endpoint of superiority vs sunitinib, meaningful clinical activity and fewer G3-4 TEAEs were observed in pts with advanced GIST treated with ripretinib after imatinib failure. Clinical trial information: NCT03673501.
Trends in Prices of Drugs Used to Treat Metastatic Non–Small Cell Lung Cancer in the US From 2015 to 2020
Desai, Aakash , Scheckel, Caleb , Jensen, Chelsee , Orme, Jacob J. , Williams, Colt , Shah, Nilay D., Leventakos, Konstantinos , Adjei, Alex A. , Jensen, Chelsee J, Shah, Nilay , Desai, Aakash P , Jensen, Chelsee J

Mayo Clinic

JAMA Network Open | January 25, 2022 | Volume: 5 | Issue: 1 | Pages: e2144923

10.1001/jamanetworkopen.2021.44923 | PMID 35076701 Get It

Ultrasound visualization of the thumb annular pulleys: A cadaveric validation study
Hoffman, Douglas F. , Hoefler, Amanda Honsvall , Bianchi, Stefano , Hoxie, Samuel C., Smith, Jay , Honsvall Hoefler, Amanda

Mayo Clinic

PM&R | January 25, 2022 | Volume: 15 | Issue: 2 | Pages: 203-211

10.1002/pmrj.12769 | PMID 35077024 Get It

AbstractBackgroundThe thumb annular pulley system is unique from the other digits and is integral to normal thumb function. Injuries to this pulley system can present a diagnostic challenge. No prior study has evaluated the ability of ultrasound (US) to evaluate all four thumb pulleys.ObjectiveTo validate the sonographic visualization of all four thumb pulleys.DesignProspective cadaveric laboratory investigation.SettingAcademic center procedural skills laboratory.ParticipantsTwelve unembalmed cadaveric hands from seven adult male donors ages 78‐89 years with body mass index 21.9‐26.6 kg/m2.InterventionsBased on anatomic descriptions, a single examiner used a standardized protocol and high‐frequency linear transducers to identify the A1, variable (Av), oblique (Ao), and A2 pulleys of the thumb in 10 cadaveric hands. As part of the validation process, the presumed Ao pulley was injected with diluted colored latex using US guidance. Two additional cadaveric specimens were dissected for detailed study of the thumb pulley system.Main Outcome MeasuresCorrelation between the four anatomic pulleys as revealed by dissection and the US findings, including identification of latex location with respect to the Ao pulley.ResultsUS correctly identified all four thumb pulleys as distinct anatomic structures and the sonographic appearance of the pulleys correlated with the dissection in all 10 specimens. Latex was observed in the Ao pulley in 100% of the cadavers.ConclusionsUltrasound can be used to accurately identify all four thumb pulleys, including distinct Ao and Av pulleys, and should be considered in the evaluation of thumb pulley injuries. This is the first study to validate the US visualization of the annular pulley system of the thumb.
The ‘other’ big complication: how chronic kidney disease impacts on cancer risks and outcomes
Lees, Jennifer S. , Elyan, Benjamin , Lang, Ninian N. , Jones, Robert J. , Mark, Patrick B. , Lang, Ninian N , Jones, Robert J , Mark, Patrick B , Herrmann, Sandra M.

Mayo Clinic

Nephrology Dialysis Transplantation | January 25, 2022 | Volume: 38 | Issue: 5 | Pages: 1071-1079

10.1093/ndt/gfac011 | PMID 35090037 Get It

ABSTRACT Cancer is the second leading cause of death in people with chronic kidney disease (CKD) after cardiovascular disease. The incidence of CKD in patients with cancer is higher than in the non-cancer population. Across various populations, CKD is associated with an elevated risk of cancer incidence and cancer death compared with people without CKD, although the risks are cancer site-specific. Higher risk of cancer is detectable in mild CKD [estimated glomerular filtration rate (eGFR) 60–89 mL/min/1.73 m2], although this risk is more obvious if sensitive markers of kidney disease are used, such as cystatin C. Independent of eGFR, albuminuria is associated with increased risk of site-specific cancer incidence and death. Here, we explore the potential mechanisms for the increased risk of cancer observed in CKD, including patient factors (shared risks such as cardiometabolic disease, obesity, smoking, diet, lifestyle and environment), disease (genetic, inflammatory and infective) and treatment factors. In particular, we discuss the ways in which renal adverse events associated with conventional chemotherapies and newer systemic anti-cancer therapies (including targeted and immunotherapies) may contribute to worse cancer outcomes in people with CKD. Finally, we review the potential benefits of acknowledging increased risk of cancer in risk prediction tools used for the management of CKD.